FRONT PHARMACOL 润色咨询

Frontiers in Pharmacology

出版年份:暂无数据 年文章数:1514 投稿命中率:52.0%

出版周期:Irregular 自引率:6.3% 审稿周期:平均2.78月

前往期刊查询

投稿信息

投稿信息
审稿速度
平均2.78月 (网友贡献,非官方数据)
投稿命中率
52.0% (网友贡献,非官方数据)
审稿费用
2950.0元/篇 (网友贡献,非官方数据)
版面费用
2812.5元/篇 (网友贡献,非官方数据)
中国人发表比例
2019年中国人文章占该期刊总数量47.75% (2018年为41.66%)
自引率
6.3 %
年文章数
1514
期刊官网
点击查看 (点击次数:23069)
点击查看 (点击次数:11862次)
作者需知
点击查看 (点击次数:2011次)
期刊简介
稿件收录要求

Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.

Pharmacology is a medical science, as was recalled in the anniversary address for the 50th Spring Meeting in Mainz of the German Pharmacological Society in March 2009. This science, of the effect of medicinal bodies, gives us the handle to clarify the fundamental processes of life. It is also the science studying the interactions between chemicals and living beings directed to prevent, ameliorate or cure the deleterious consequences of their diseases, thereby providing medicine with weapons against diseases. Those major targets offer the opportunity to segment the field not only in studies considering pure basic topics but also by integrating basic and clinical science. This journal's editorial policy aims at identifying the most productive research projects through an evaluation by the scientific community and emphasizing proper use of translational science at both preclinical and clinical levels. Editors encourage collaboration between clinicians and basic scientists and welcome papers issued from a collaborative strategy between the academic and the private industrial sectors that could assist in the reversal of the current decline in the production of original medicines.

打开APP